Dipentum Related Published Studies
Well-designed clinical trials related to Dipentum (Olsalazine)
A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. [2004.06]
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. [2001.10]
The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. [1999.03]
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. [1998.08]
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. [1996.11]
Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. [1996.05.01]
Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. [1996.04]
Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. [1995.05]
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. [1995.03]
Optimum dose of olsalazine for maintaining remission in ulcerative colitis. [1994.09]
Effect of olsalazine and mesalazine on intraluminal pH of the duodenum and proximal jejunum in healthy humans. [1994.06]
Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. [1993.10]
Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. [1993.07]
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. [1992.05.23]
Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. [1992.04]
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. [1992.02]
Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. [1991.04]
Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. [1990.11]
Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. [1990.05]
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. [1989.10]
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. [1989.05]
Olsalazine does not increase the bile acid losses in subjects with a permanent ileostomy. [1988.05]
Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. [1988]
Olsalazine in the treatment of mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind, clinical trial. [1988]
Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects. [1988]
Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis. [1988]
Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. [1988]
Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. [1988]
Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. [1987.12]
Well-designed clinical trials possibly related to Dipentum (Olsalazine)
[Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates] [2006.10.15]
Different therapy for different types of ulcerative colitis in China. [2004.05.15]
Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. [2002.02]
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. [1997.03]
Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. [1996.08]
Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. [1994.06]
Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. [1993.04]
Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. [1992.10]
Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. [1988.01]
Other research related to Dipentum (Olsalazine)
Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study. [2006.05]
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. [2005.03]
Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. [2002.04]
Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. [2000.11]
Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. [1998.09]
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. [1997.10]
Olsalazine-induced lupus syndrome. [1997]
5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. [1996.12]
Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. [1995.05]
Olsalazine in ankylosing spondylitis: a pilot study. [1994.09]
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? [1993.04]
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. [1992.06]
Olsalazine-related diarrhoea: does rat intestine adapt in vivo? [1992.04]
Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. [1991.04]
Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. [1988.07]
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. [1988.06]
Olsalazine as an alternative therapy in a patient with sulfasalazine-induced eosinophilic pneumonia. [1988.04]
Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention: a follow-up study. [1988]
Induction of and adaptation to olsalazine induced intestinal volume load. [1988]
Olsalazine-O-sulphate: an acid labile metabolite of olsalazine. [1988]
The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. [1988]
Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term. [1988]
Pharmacology of olsalazine. [1988]
Clinical tolerance of olsalazine. [1988]
Evolution of olsalazine. [1988]
Pharmacokinetics of olsalazine and its metabolites. [1988]
Influence of olsalazine on gastrointestinal transit in ulcerative colitis. [1987.11]
Olsalazine in patients intolerant of sulphasalazine. [1987.11]
Effect of olsalazine sodium on migrating motor complexes in the upper small bowel of human volunteers. [1987]
Other possibly related research studies
Drug therapy for ulcerative colitis. [2004.08.15]
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. [2004.03]
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. [2004.01.15]
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. [2003.01]
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. [2003.05]
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. [2002]
5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. [2000.02]
Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. [1999.10]
[Pregnancy outcome in inflammatory bowel diseases] [1999.05]
A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs. [1997.10.15]
Sensorineural hearing loss and ulcerative colitis. [1997.03]
Bioavailability of controlled release mesalazine (5-ASA) preparations. [1995.11]
Medical therapy for ulcerative colitis in childhood. [1994.02]
Outpatient management of inflammatory bowel disease. Let's keep it as simple as possible. [1992.11.01]
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. [1992.11]
Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. [1992.10]
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. [1992.08]
New drugs on the horizon. [1992.04]
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. [1992.02]
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. [1992.01.22]
Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. [1989.12]
5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation. [1989.06]
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. [1988.10]
[New treatments of hemorrhagic rectocolitis] [1988.06]
Pancreatitis induced by disodium azodisalicylate. [1988.05]
Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update. [1987.12]
[New forms of 5-aminosalicylate in inflammatory intestinal lesions] [1987.11]
Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. [1987.08]
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. [2005.11]
Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. [2005.06]
Mesalamine delivery systems: do they really make much difference? [2005.01.06]
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. [2005.01.06]
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. [2003.09]
Pharmaceutical approaches to colon targeted drug delivery systems. [2003.01]
|
